MA53607A - (r)-5-carbamoylpyridin-3-yl-2-méthyl-4-(3-(trifluorométhoxy)benzyl) pipérazine-1-carboxylate cristallin, compositions et procédés d'utilisation associés - Google Patents

(r)-5-carbamoylpyridin-3-yl-2-méthyl-4-(3-(trifluorométhoxy)benzyl) pipérazine-1-carboxylate cristallin, compositions et procédés d'utilisation associés

Info

Publication number: MA53607A
Authority: MA; Morocco
Prior art keywords: carbamoylpyridin; trifluoromethoxy; piperazine; carboxylate; benzyl
Prior art date: 2018-09-13

Application number

MA053607A

Other languages

English (en)

Other versions

MA53607B1 (fr

Inventor

Lianfeng Huang

Nancy Tsou

Nicole Suzanne White

Jun Xu

Qun Zhang

Original Assignee

Abide Therapeutics Inc

Celgene Corp

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-09-13

Filing date

2019-09-12

Publication date

2021-12-22

2019-09-12 Application filed by Abide Therapeutics Inc, Celgene Corp filed Critical Abide Therapeutics Inc

2021-12-22 Publication of MA53607A publication Critical patent/MA53607A/fr

2025-05-30 Publication of MA53607B1 publication Critical patent/MA53607B1/fr

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
- C07D211/94—Oxygen atom, e.g. piperidine N-oxide
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Pain & Pain Management (AREA)
Rheumatology (AREA)
Epidemiology (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

MA53607A 2018-09-13 2019-09-12 (r)-5-carbamoylpyridin-3-yl-2-méthyl-4-(3-(trifluorométhoxy)benzyl) pipérazine-1-carboxylate cristallin, compositions et procédés d'utilisation associés MA53607B1 (fr)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US201862731014P	2018-09-13	2018-09-13
PCT/US2019/050771 WO2020056105A1 (fr)	2018-09-13	2019-09-12	(r)-5-carbamoylpyridin-3-yl-2-méthyl-4-(3-(trifluorométhoxy)benzyl) pipérazine-1-carboxylate cristallin, compositions et procédés d'utilisation associés
EP19778721.1A EP3849970B1 (fr)	2018-09-13	2019-09-12	(r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl)piperazine-1-carboxylate cristallin, compositions et procedes pour leur utilisaton.

Publications (2)

Publication Number	Publication Date
MA53607A true MA53607A (fr)	2021-12-22
MA53607B1 MA53607B1 (fr)	2025-05-30

Family

ID=68069873

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
MA53607A MA53607B1 (fr)	2018-09-13	2019-09-12	(r)-5-carbamoylpyridin-3-yl-2-méthyl-4-(3-(trifluorométhoxy)benzyl) pipérazine-1-carboxylate cristallin, compositions et procédés d'utilisation associés

Country Status (28)

Country	Link
US (4)	US11053199B2 (fr)
EP (2)	EP4434583B1 (fr)
JP (1)	JP7405840B2 (fr)
KR (1)	KR102844245B1 (fr)
CN (3)	CN118561814A (fr)
AU (1)	AU2019337623B2 (fr)
BR (1)	BR112021004340A2 (fr)
CA (1)	CA3112200A1 (fr)
CL (1)	CL2021000596A1 (fr)
CO (1)	CO2021003295A2 (fr)
DK (1)	DK3849970T3 (fr)
EA (1)	EA202190511A1 (fr)
ES (1)	ES2993173T3 (fr)
FI (1)	FI3849970T3 (fr)
HR (1)	HRP20241294T1 (fr)
HU (1)	HUE068147T2 (fr)
IL (1)	IL281276B2 (fr)
LT (1)	LT3849970T (fr)
MA (1)	MA53607B1 (fr)
MX (1)	MX2021002923A (fr)
MY (2)	MY210363A (fr)
PL (1)	PL3849970T3 (fr)
PT (1)	PT3849970T (fr)
RS (1)	RS65967B1 (fr)
SG (1)	SG11202102143RA (fr)
SI (1)	SI3849970T1 (fr)
SM (1)	SMT202400369T1 (fr)
WO (1)	WO2020056105A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU2019337623B2 (en)	2018-09-13	2024-12-05	Celgene Corporation	Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1- carboxylate, compositions and methods of use thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI385164B (zh)	2005-02-17	2013-02-11	Astellas Pharma Inc	Pyridyl non-aromatic nitrogen-containing heterocyclic-1-carboxylate derivatives (II)
EP3099332A4 (fr) *	2014-01-29	2017-06-21	Madrigal Pharmaceuticals, Inc.	Agents thérapeutiques cibles
EP4335848A3 (fr)	2017-03-13	2024-06-19	Lundbeck La Jolla Research Center, Inc.	Inhibiteurs doubles de magl et de faah
AU2019337623B2 (en)	2018-09-13	2024-12-05	Celgene Corporation	Crystalline (r)-5-carbamoylpyridin-3-yl-2-methyl-4-(3-(trifluoromethoxy)benzyl) piperazine-1- carboxylate, compositions and methods of use thereof

2019
- 2019-09-12 AU AU2019337623A patent/AU2019337623B2/en active Active
- 2019-09-12 MY MYPI2024007477A patent/MY210363A/en unknown
- 2019-09-12 CA CA3112200A patent/CA3112200A1/fr active Pending
- 2019-09-12 CN CN202410683425.0A patent/CN118561814A/zh active Pending
- 2019-09-12 DK DK19778721.1T patent/DK3849970T3/da active
- 2019-09-12 JP JP2021514123A patent/JP7405840B2/ja active Active
- 2019-09-12 PT PT197787211T patent/PT3849970T/pt unknown
- 2019-09-12 MX MX2021002923A patent/MX2021002923A/es unknown
- 2019-09-12 MY MYPI2021001295A patent/MY208901A/en unknown
- 2019-09-12 EA EA202190511A patent/EA202190511A1/ru unknown
- 2019-09-12 SI SI201930824T patent/SI3849970T1/sl unknown
- 2019-09-12 KR KR1020217010747A patent/KR102844245B1/ko active Active
- 2019-09-12 US US16/569,578 patent/US11053199B2/en active Active
- 2019-09-12 HU HUE19778721A patent/HUE068147T2/hu unknown
- 2019-09-12 LT LTEPPCT/US2019/050771T patent/LT3849970T/lt unknown
- 2019-09-12 SG SG11202102143RA patent/SG11202102143RA/en unknown
- 2019-09-12 PL PL19778721.1T patent/PL3849970T3/pl unknown
- 2019-09-12 CN CN202410683444.3A patent/CN118530218A/zh active Pending
- 2019-09-12 FI FIEP19778721.1T patent/FI3849970T3/fi active
- 2019-09-12 HR HRP20241294TT patent/HRP20241294T1/hr unknown
- 2019-09-12 CN CN201980060119.9A patent/CN113227069B/zh active Active
- 2019-09-12 MA MA53607A patent/MA53607B1/fr unknown
- 2019-09-12 RS RS20241039A patent/RS65967B1/sr unknown
- 2019-09-12 BR BR112021004340-3A patent/BR112021004340A2/pt unknown
- 2019-09-12 SM SM20240369T patent/SMT202400369T1/it unknown
- 2019-09-12 WO PCT/US2019/050771 patent/WO2020056105A1/fr not_active Ceased
- 2019-09-12 IL IL281276A patent/IL281276B2/en unknown
- 2019-09-12 EP EP24185102.1A patent/EP4434583B1/fr active Active
- 2019-09-12 EP EP19778721.1A patent/EP3849970B1/fr active Active
- 2019-09-12 ES ES19778721T patent/ES2993173T3/es active Active
2021
- 2021-03-10 CL CL2021000596A patent/CL2021000596A1/es unknown
- 2021-03-12 CO CONC2021/0003295A patent/CO2021003295A2/es unknown
- 2021-06-03 US US17/338,182 patent/US11680046B2/en active Active
2023
- 2023-05-05 US US18/143,765 patent/US12410133B2/en active Active
2025
- 2025-08-06 US US19/292,473 patent/US20260062384A1/en active Pending

Also Published As

Publication number	Publication date
CN113227069A (zh)	2021-08-06
CO2021003295A2 (es)	2021-07-30
CN118561814A (zh)	2024-08-30
US12410133B2 (en)	2025-09-09
KR102844245B1 (ko)	2025-08-11
MY208901A (en)	2025-06-09
AU2019337623B2 (en)	2024-12-05
BR112021004340A2 (pt)	2021-05-25
US20230382861A1 (en)	2023-11-30
EP3849970B1 (fr)	2024-07-03
AU2019337623A1 (en)	2021-05-13
HRP20241294T1 (hr)	2024-12-06
JP7405840B2 (ja)	2023-12-26
MY210363A (en)	2025-09-13
PT3849970T (pt)	2024-09-25
PL3849970T3 (pl)	2025-01-07
EP4434583A2 (fr)	2024-09-25
WO2020056105A9 (fr)	2020-05-28
HUE068147T2 (hu)	2024-12-28
US11680046B2 (en)	2023-06-20
EP4434583A3 (fr)	2024-11-20
JP2022500441A (ja)	2022-01-04
CL2021000596A1 (es)	2021-07-30
IL281276B1 (en)	2024-09-01
US20210363105A1 (en)	2021-11-25
CA3112200A1 (fr)	2020-03-19
SG11202102143RA (en)	2021-04-29
EP4434583B1 (fr)	2026-04-01
KR20210057789A (ko)	2021-05-21
EA202190511A1 (ru)	2021-07-05
DK3849970T3 (da)	2024-09-30
WO2020056105A1 (fr)	2020-03-19
MX2021002923A (es)	2021-09-08
IL281276A (en)	2021-04-29
US11053199B2 (en)	2021-07-06
MA53607B1 (fr)	2025-05-30
EP3849970A1 (fr)	2021-07-21
FI3849970T3 (fi)	2024-09-20
CN118530218A (zh)	2024-08-23
IL281276B2 (en)	2025-01-01
ES2993173T3 (en)	2024-12-23
SMT202400369T1 (it)	2024-11-15
US20260062384A1 (en)	2026-03-05
RS65967B1 (sr)	2024-10-31
CN113227069B (zh)	2024-11-05
US20200095201A1 (en)	2020-03-26
SI3849970T1 (sl)	2024-11-29
LT3849970T (lt)	2024-10-10

Publication	Publication Date	Title
EP3962296A4 (fr)	2023-02-08	Compositions de cannabinoïdes et procédés d'utilisation
MA56032A (fr)	2022-04-06	Composés, compositions et procédés d'utilisation
MA52781A (fr)	2021-04-14	Anticorps contre entpd2, polythérapies, et procédés d'utilisation des anticorps et des polythérapies
MA53235A (fr)	2022-04-27	Indoles substitués et procédés d'utilisation associés
EP3704239A4 (fr)	2021-08-18	Compositions de casz et procédés d'utilisation
MA54397A (fr)	2022-05-11	Compositions microbiennes comprenant de l'ellagitannine et procédés d'utilisation
EP3935155A4 (fr)	2022-11-23	Polypeptides effecteurs crispr-cas et procédés d'utilisation associés
EP3768267A4 (fr)	2022-04-20	Composés inhibiteurs de kinase, compositions et procédés d'utilisation
EP3917543A4 (fr)	2022-10-12	Compositions de nitrate améliorées et procédés d'utilisation
EP3891272A4 (fr)	2023-03-29	Compositions et procédés d'immunothérapie
EP3621660A4 (fr)	2021-01-20	Compositions et procédés d'utilisation de capsides arc
EP3803403A4 (fr)	2022-07-13	Compositions et procédés d'imagerie
MA48942A (fr)	2020-04-08	Composés thérapeutiques, compositions et procédés d'utilisation associés
MA54148A (fr)	2022-02-09	Mélanges et compositions comprenant de la 5-fluoro-4-imino-3-méthyl-1-tosyl-3,4-dihydropyrimidin-2-one et leurs procédés d'utilisation
EP3911355A4 (fr)	2022-06-01	Lubricines recombinantes, compositions et procédés d'utilisation de celles-ci
EP3914608A4 (fr)	2023-05-17	Nouvelles protéines d'inhibition des insectes
EP4074711A4 (fr)	2024-04-17	Inhibiteur de l'autotaxine hétérocyclique contenant de l'azote, composition le contenant et son utilisation
EP3826468A4 (fr)	2022-04-27	Compositions pour l'agriculture et procédés associés
MA55079A (fr)	2022-04-06	Composition et récipient, kit, procédé d'utilisation
EP3965776A4 (fr)	2023-08-02	Compositions oligosaccharidiques et leurs procédés d'utilisation
EP4058035A4 (fr)	2023-12-27	Compositions et procédés d'immunothérapie
EP3801021A4 (fr)	2022-03-09	Procédés et compositions sporicides
EP3906233A4 (fr)	2022-09-14	Composés inhibiteurs de kinase, compositions et procédés d'utilisation
MA53607A (fr)	2021-12-22	(r)-5-carbamoylpyridin-3-yl-2-méthyl-4-(3-(trifluorométhoxy)benzyl) pipérazine-1-carboxylate cristallin, compositions et procédés d'utilisation associés
EP3773531A4 (fr)	2021-06-23	Compositions polymorphes cristallines a2-73 de matière et leurs procédés d'utilisation